2024-514942-35-00招募中1 期
"A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies"
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.14 个研究点 分布在 6 个国家目标入组 8 人开始时间: 2025年3月7日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 8
- 试验地点
- 14
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (14)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the BodyNCT07273474Boehringer Ingelheim12
招募中
1 期
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer2023-510307-22-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.116
已完成
1 期
A study in healthy people to test whether BI 1291583 influences the amount of dabigatran in the body2024-516256-18-00Boehringer Ingelheim International GmbH14
招募中
1 期
A study to test how different doses of BI 3731579 are tolerated by healthy people2024-517209-95-00Boehringer Ingelheim International GmbH40
暂停
1 期
A study in healthy men to test how BI 1839100 is taken up and handled by the body2024-510870-26-00Boehringer Ingelheim International GmbH16